Drug Farm Signs Agreement with National Institutes of Health (NIH) to Develop Precision Targeted Treatment for ROSAH Syndrome
Drug Farm Signs Agreement with National Institutes of Health (NIH) to Develop Precision Targeted Treatment for ROSAH Syndrome
12/19/24, 9:47 PM
Location
shanghaiType
agreement
Drug Farm, a clinical-stage biopharmaceutical company, announced the signing of a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to develop a precision targeted drug, DF-003, for the treatment of ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) syndrome.
Company Info
Location
shanghai, shanghai, china
Additional Info
Drug Farm is a China- and US-based biotech developing innovative treatments targeting innate immunity for HBV, cancer, and autoimmune diseases. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. IDInVivo technology allows the direct assessment of gene targets in living animals with intact immune systems. Using the IDInVivo platform, Drug Farm has identified novel innate immunity pathways and targets and is now rapidly advancing multiple first-in-class drug candidates into clinical development. For more information please visit: www.drug-farm.com/